Scott M. Lippman graduated from Johns Hopkins University School of Medicine and did his internship and residency training at Johns Hopkins Hospital and Harbor-UCLA Medical Center. He had hematology/medical oncology training at Stanford University and the University of Arizona and is triple board-certified in internal medicine, hematology and medical oncology.
Until becoming the director of Moores Cancer Center at the University of California, San Diego a little over a year ago, Lippman was chair of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. Lippman is also a professor of medicine at UC San Diego and holds the Chugai Pharmaceutical Chair in Cancer. Lippman currently serves on the National Institutes of Health Clinical Trials/Translational Research Advisory Committee and has previously been a leader of many American Association for Cancer Research (AACR) and American Society of Clinical Oncology committees and programs, serving on several cancer center external advisory boards and major-trial committees.
Lippman has authored over 300 publications in research journals and medical texts books and has served on editing boards for top-tier, peer-reviewed journals, including Cancer Research, Journal of the National Cancer Institute, and Journal of Clinical Oncology. He was also made editor-in-chief of AACR’s Cancer Prevention Research.
In an interview with AACR, Lippman talks about the importance of these journals within cancer research as a whole. He explains how doctors are so focused on their specializations and in depth research that sometimes they have a hard time branching out and seeing the relevance of different disciplines. With his wide variety of expertise, Lippman embodies the notion he promotes in his editing of finding applications of other studies.
In this interview, Lippman also discusses the revelation of personalized prevention and care. Cancer is a complex disease that takes many forms and affects people differently. Lippman claims that treatments should be tailored to certain markers in the patient that will help predict how the patient and the cancer will respond. With this personalized treatment, Lippman also suggests the possibility of personalized prevention, informing patients of what they can do to combat their potential for developing cancer.
Watch the interview below and hear what he has to say about diversifying ones’ scope with research journals and specializing research in personalized cancer prevention.
Or, get the chance to see Lippman discuss his studies in person at this year’s The Atlantic Meets the Pacific, hosted by UC San Diego Extension and The Atlantic Magazine. The conference will be held during October 2 through 4 at Scripps Seaside Forum and the Qualcomm Institute in La Jolla, California. For more information on speakers and registration, please visit atlanticmeetspacific.com.